Skip to content

A comparison of menstrual volume and other benefits between Estradiol valerate/dienogest and Ethinyl estradiol/desogestrel: A randomized controlled trial

A comparison of menstrual volume and other benefits between Estradiol valerate/dienogest and Ethinyl estradiol/desogestrel: A randomized controlled trial

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240908003
Enrollment
36
Registered
2024-09-08
Start date
2024-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amount of menstrual bleed in patient who use Estradiol valerate/dienogest and Ethinyl estradiol/desogestrel use Heavy menstrual blood loss, contraception, oral contraceptive pill, hormonal contraceptive pill

Interventions

Oral contraceptive pills Each wallet contains 26 colored active tablets and 2 white inactive-tablets. ESTRADIOL VALERATE (3 mg, 2mg, 1mg) DIENOGEST (2 mg, 3mg) Take one tablet every day and should
Active Comparator Drug,Active Comparator Drug
Estradiol valerate/dienogest contraceptive pills ,Ethynyl estradiol/desogestrel contraceptive pills

Sponsors

Srinakharinwirot university
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1 Thai Female aged 18 to 40 years at the outpatient department of the HRH Princess Maha Chakri Sirindhorn Medical Center and who wish to use oral contraceptives for contraception. 2 Not currently taking hormonal medications for at least 6 months prior, or anticoagulant medications. 3 No history of drug allergies or adverse effects from hormonal medications.

Exclusion criteria

Exclusion criteria: 1 Body Mass Index greater than 30 kg per m2 2 Smoking more than 20 cigarettes per day 3 Patients with abnormal cervical cell test results, detected endometrial pathology, or abnormal uterine fibroids from transvaginal or abdominal ultrasound . 4 Patients with abnormal liver function test results from blood tests. 5 Pregnancy 6 Excluded if they have any of the following conditions: history of deep vein thrombosis/stroke/coronary artery disease, breast cancer or suspected breast cancer, liver disease or impaired liver function, ovarian cancer, uterine cancer, pregnancy or suspected pregnancy, or uncontrolled hypertension.

Design outcomes

Primary

MeasureTime frame
Amount of menstrual bleed 4 months Pictograms

Secondary

MeasureTime frame
side effect of hormone: nausea and vomiting, breast tenderness, weight gain, spotting or headache 4 months Patient reported outcome using a questionnaire interview

Countries

Thailand

Contacts

Public ContactChanita Sirakulawat

Srinakarinwirot university

nutsrkw@gmail.com0988699217

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026